These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 31242460)
1. Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases. Zhu X; Yang H; Lang J; Zhang Y Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():103-108. PubMed ID: 31242460 [TBL] [Abstract][Full Text] [Related]
2. The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer. Zhu X; Zhao L; Lang J Int J Gynecol Cancer; 2018 Oct; 28(8):1514-1519. PubMed ID: 30045136 [TBL] [Abstract][Full Text] [Related]
3. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer]. Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477 [No Abstract] [Full Text] [Related]
4. Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers. Ma L; Guo Q; Ma Y; Liu FR; Shen XY Eur J Gynaecol Oncol; 2009; 30(4):370-4. PubMed ID: 19761124 [TBL] [Abstract][Full Text] [Related]
5. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors]. Ma L; Zhang JH; Liu FR; Zhang X Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549 [TBL] [Abstract][Full Text] [Related]
7. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma. S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147 [TBL] [Abstract][Full Text] [Related]
8. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients. Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993 [TBL] [Abstract][Full Text] [Related]
9. Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Fendri A; Masmoudi A; Khabir A; Sellami-Boudawara T; Daoud J; Frikha M; Ghorbel A; Gargouri A; Mokdad-Gargouri R Cancer Biol Ther; 2009 Mar; 8(5):444-51. PubMed ID: 19221469 [TBL] [Abstract][Full Text] [Related]
10. Relationship between RAS Association Domain Family Protein 1A Promoter Methylation and the Clinicopathological Characteristics in Patients with Ovarian Cancer: A Systematic Meta-Analysis. Wang H; Cui M; Zhang S; He J; Song L; Chen Y Gynecol Obstet Invest; 2018; 83(4):349-357. PubMed ID: 29130987 [TBL] [Abstract][Full Text] [Related]
11. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018 [TBL] [Abstract][Full Text] [Related]
12. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer. Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007 [TBL] [Abstract][Full Text] [Related]
13. Promoter Methylation of RASSF1A Gene in Egyptian Patients with Ovarian Cancer. Rezk NA; Mohamed RH; Alnemr AA; Harira M Appl Biochem Biotechnol; 2018 May; 185(1):153-162. PubMed ID: 29098560 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma. Buderath P; Mairinger F; Mairinger E; Böhm K; Mach P; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A; Westerwick D; Hager T Int J Gynecol Cancer; 2019 Nov; 29(9):1389-1395. PubMed ID: 31492714 [TBL] [Abstract][Full Text] [Related]
15. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945 [TBL] [Abstract][Full Text] [Related]
16. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer. Mao WM; Li P; Zheng QQ; Wang CC; Ge MH; Hu FJ; Fang XH; Dong ZM; Ling ZQ Arch Med Res; 2011 Apr; 42(3):182-8. PubMed ID: 21722812 [TBL] [Abstract][Full Text] [Related]
18. Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation. Parvathareddy SK; Siraj AK; Al-Badawi IA; Tulbah A; Al-Dayel F; Al-Kuraya KS Sci Rep; 2021 Feb; 11(1):3750. PubMed ID: 33580098 [TBL] [Abstract][Full Text] [Related]
19. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients. Rasti M; Tavasoli P; Monabati A; Entezam M Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345 [TBL] [Abstract][Full Text] [Related]
20. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Yeo W; Wong N; Wong WL; Lai PB; Zhong S; Johnson PJ Liver Int; 2005 Apr; 25(2):266-72. PubMed ID: 15780049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]